Elios' customized cancer vaccine shows positive results
Elios Therapeutics' personalized cancer vaccine shows a long-term survival benefit for patients with stage III or IV melanoma, according to final data from its clinical trial. Read More
Celularity begins trial of COVID-19 cell therapy
Celularity has received funding to support a phase I/II clinical trial of human placental hematopoietic stem cell-derived natural killer cells for the treatment of COVID-19. Read More
Taysha gets $95M in financing to advance gene therapies
Taysha Gene Therapies has closed on $95 million in series B financing to advance gene therapies for monogenic central nervous system diseases. Read More
Bio-Rad wins appeal in 10x Genomics patent infringement ruling
Bio-Rad Laboratories said that the U.S. Court of Appeals for the Federal Circuit has affirmed a lower court ruling that 10x Genomics had willfully infringed a patent that had been exclusively licensed to Bio-Rad by the University of Chicago. Read More
Direct Biologics begins phase II trial for COVID-19 ExoFlo therapy
Regenerative medical products manufacturer Direct Biologics has won approval from the U.S. Food and Drug Administration to study its ExoFlo therapy in a clinical trial with COVID-19 patients. Read More
Omega Therapeutics advances epigenomic programming platform
Omega Therapeutics has received $85 million in financing to support clinical trials of its epigenomic controllers for programs in oncology, inflammation, autoimmune, metabolic, and rare genetic diseases. Read More
Avacta, Daewoong partner on COVID-19 therapy
Avacta has expanded its collaboration with Daewoong Pharmaceutical to develop stem cell treatments using Avacta's neutralizing Affimer therapy for COVID-19 patients. Read More
Carisma advances macrophage immunotherapy
Carisma Therapeutics' engineered macrophage immunotherapy has cleared an investigational new drug application through the U.S. Food and Drug Administration. The company intends to initiate a phase I clinical trial for the candidate this year. Read More
Amyris partners with IDRI on scalable vaccine platform
Amyris and the Infectious Disease Research Institute (IDRI) have inked a binding term sheet for the development of a planned COVID-19 RNA vaccine technology platform. Read More
Synaffix, ADC Therapeutics collaborate on antibody drug conjugates
Synaffix and ADC Therapeutics have expanded an existing collaboration to explore additional applications of Synaffix's site-specific conjugation technologies. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter